B M Wolpin

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer
    Brian M Wolpin
    Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02215, USA
    J Natl Cancer Inst 105:1027-35. 2013
  2. pmc Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer
    B M Wolpin
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Ann Oncol 24:1792-801. 2013
  3. pmc Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 70:1015-23. 2010
  4. pmc Prospective study of ABO blood type and the risk of pulmonary embolism in two large cohort studies
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Thromb Haemost 104:962-71. 2010
  5. pmc Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 19:3140-9. 2010
  6. pmc Plasma 25-hydroxyvitamin D and risk of pancreatic cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Cancer Epidemiol Biomarkers Prev 21:82-91. 2012
  7. pmc ABO blood group and the risk of pancreatic cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 101:424-31. 2009
  8. pmc Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:176-85. 2009
  9. pmc Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:193-8. 2009
  10. pmc Prediagnostic plasma folate and the risk of death in patients with colorectal cancer
    Brian M Wolpin
    Department of MedicalOncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 26:3222-8. 2008

Detail Information

Publications28

  1. pmc Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer
    Brian M Wolpin
    Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02215, USA
    J Natl Cancer Inst 105:1027-35. 2013
    ..Hemoglobin A1c (HbA1c) is a measure of hyperglycemia, whereas plasma insulin and proinsulin are markers of peripheral insulin resistance, and the proinsulin to insulin ratio marks pancreatic β-cell dysfunction...
  2. pmc Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer
    B M Wolpin
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Ann Oncol 24:1792-801. 2013
    ..We evaluated AGS-1C4D4, a fully human monoclonal antibody to prostate stem cell antigen (PSCA), with gemcitabine in a randomized, phase II study of metastatic pancreatic cancer...
  3. pmc Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 70:1015-23. 2010
    ..68 (95% CI, 2.03-3.54) compared with nonsmokers of blood type O. We concluded that ABO genotypes were significantly associated with pancreatic cancer risk...
  4. pmc Prospective study of ABO blood type and the risk of pulmonary embolism in two large cohort studies
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Thromb Haemost 104:962-71. 2010
    ..04). In two large, prospective cohorts, ABO blood type was significantly associated with the risk of idiopathic and non-idiopathic PE, with even greater risk for idiopathic PE among current and past smokers with non-O blood type...
  5. pmc Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 19:3140-9. 2010
    ..We hypothesized: 1) A(1) allele would confer greater risk than A(2) allele, 2) protective effect of the O allele would be equivalent for O01 and O02 variants, 3) secretor phenotype would modify the association with risk...
  6. pmc Plasma 25-hydroxyvitamin D and risk of pancreatic cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Cancer Epidemiol Biomarkers Prev 21:82-91. 2012
    ..Laboratory studies suggest that vitamin D may inhibit pancreatic cancer cell growth. However, epidemiologic studies of vitamin D and pancreatic cancer risk have been conflicting...
  7. pmc ABO blood group and the risk of pancreatic cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 101:424-31. 2009
    ..ABO blood type is an inherited characteristic that in previous small studies has been associated with the risk of gastrointestinal malignancies...
  8. pmc Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:176-85. 2009
    ..Excess energy balance leads to increased circulating insulin and depressed levels of circulating insulin-like growth factor binding protein (IGFBP) -1, which promote cancer cell growth in preclinical models...
  9. pmc Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:193-8. 2009
    ..We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line therapy with gemcitabine...
  10. pmc Prediagnostic plasma folate and the risk of death in patients with colorectal cancer
    Brian M Wolpin
    Department of MedicalOncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 26:3222-8. 2008
    ..Therefore, high priority has been given to research investigating the influence of folate on cancer progression in patients with colorectal cancer...
  11. ncbi request reprint Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, MA 02115, USA
    Cancer Res 67:7923-8. 2007
    ..30; 95% CI, 1.48-7.35). Among participants in four U.S. prospective cohort studies, low plasma IGFBP-1 levels significantly predicted an increased risk of pancreatic cancer...
  12. pmc Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts
    B M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Cancer 97:98-104. 2007
    ..In four prospective cohorts, we found no association between the risk of pancreatic cancer and prediagnostic plasma levels of IGF-I, IGF-II, or IGFBP-3...
  13. pmc Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies
    Y Bao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Br J Cancer 102:1422-7. 2010
    ..Studies evaluating vitamin D status in relation to pancreatic cancer risk have yielded inconsistent results...
  14. ncbi request reprint Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer
    B M Wolpin
    Dana Farber Cancer Institute, Boston, MA Massachusetts General Hospital, Boston, MA
    J Clin Oncol 26:4614. 2008
    ..We performed a phase II study of RAD001, an oral inhibitor of mTOR (mammalian target of rapamycin), in patients with metastatic PDAC whose tumors progressed on gemcitabine...
  15. pmc Nut consumption and risk of pancreatic cancer in women
    Y Bao
    Channing Division of Network Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Br J Cancer 109:2911-6. 2013
    ..Increasing nut intake has been associated with reduced risk of diabetes mellitus, which is a risk factor for pancreatic cancer...
  16. ncbi request reprint Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET)
    J A Chan
    Dana Farber Cancer Institute, Boston, MA Division of Hematology and Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
    J Clin Oncol 29:4120. 2011
    ..We performed a phase I study to evaluate safety and feasibility of combining pasireotide and everolimus in patients with advanced NETs...
  17. ncbi request reprint Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC)
    B M Wolpin
    Dana Farber Cancer Institute, Boston, MA Memorial Sloan Kettering Cancer Center, New York, NY Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada Division of Hematology and Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA Northwest Kaiser Permanente, Portland, OR University of Miami Sylvester Comprehensive Cancer Center, Miami, FL Medical College of Wisconsin, Milwaukee, WI Vanderbilt University Medical Center, Nashville, TN Cross Cancer Institute, Edmonton, AB, Canada Hospital Vall d Hebron, Barcelona, Spain Juravinski Cancer Centre, Hamilton, ON, Canada Chu Estaing, Clermond Ferrand, France N N Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia Leningrad Regional Oncology Center, St Petersburg, Russia Agensys, Santa Monica, CA Centro Integral Oncológico Clara Campal, Madrid, Spain
    J Clin Oncol 29:4031. 2011
    ..4031 Background: A is a fully human monoclonal antibody directed against prostate stem cell antigen (PSCA), a cell surface protein expressed on pancreatic cancer cells...
  18. pmc Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741
    Charles S Fuchs
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:8263-9. 2008
    ..We examined the influence of baseline plasma levels of IGF-I, IGF-II, IGFBP-3, and C-peptide on outcome among patients receiving first-line chemotherapy for metastatic colorectal cancer...
  19. pmc ABO blood group and risk of colorectal cancer
    Hamed Khalili
    Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Epidemiol Biomarkers Prev 20:1017-20. 2011
    ..Recent studies have shown an association between non-O blood group and risk of pancreatic cancer. It is unclear whether this association is observed with other gastrointestinal malignancies, including colorectal cancers...
  20. ncbi request reprint A single-arm trial of panitumumab in cetuximab refractory KRAS wild-type colorectal cancer
    R C Wadlow
    Massachusetts General Hospital, Boston, MA James P Wilmot Cancer Center, University of Rochester, Rochester, NY Dana Farber Cancer Institute, Boston, MA Massachusetts General Hospital Cancer Center, Boston, MA Massachusetts General Hospital Cancer Center Harvard Medical School, Boston, MA
    J Clin Oncol 29:428. 2011
    ..The value of panitumumab as a salvage agent in cetuximab-resistant colorectal cancer is unknown...
  21. pmc Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer
    K Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Cancer 101:916-23. 2009
    ....
  22. pmc A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
    J A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 22:1367-73. 2011
    ..We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against EGFR, in patients with unresectable or metastatic esophageal or gastric adenocarcinoma...
  23. pmc A cohort study of p27 localization in colon cancer, body mass index, and patient survival
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Brigham and Women s Hospital, Boston, and Harvard Medical School 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:1849-58. 2009
    ..08). In conclusion, p27 alterations in colon cancer are associated with superior prognosis. Adverse prognostic effect of obesity seems limited to patients with nuclear p27 expression, suggesting a host-tumor interaction...
  24. pmc A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis
    Shuji Ogino
    Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, 44 Binney St, Room JF 215C, Boston, Massachusetts 02115, USA
    Am J Gastroenterol 104:2047-56. 2009
    ..STMN1 activity is influenced by p53, p27, and the PI3K/AKT pathway. However, its prognostic significance in colon cancer is uncertain...
  25. pmc Systemic treatment of colorectal cancer
    Brian M Wolpin
    Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 134:1296-310. 2008
    ....
  26. ncbi request reprint Adjuvant treatment of colorectal cancer
    Brian M Wolpin
    Dana Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA
    CA Cancer J Clin 57:168-85. 2007
    ..Current randomized clinical trials in the adjuvant therapy of colorectal cancer are examining the value of adding agents known to be active in metastatic disease, including those that modify specific molecular targets...
  27. ncbi request reprint CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Virchows Arch 450:529-37. 2007
    ..Additional studies are necessary to examine the role of DNA methylation in treatment efficacy...
  28. ncbi request reprint Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:208-13. 2006
    ....